| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
In today's rapidly changing and fiercely competitive business landscape, it is essential for investors and industry enthusiasts to thoroughly analyze companies. In this article, we will conduct a comprehensive industry comparison, evaluating Merck & Co (NYSE:MRK) against its key competitors in the Pharmaceuticals industry. By examining key financial metrics, market position, and growth prospects, we aim to provide valuable insights for investors and shed light on company's performance within the industry.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
| Company | P/E | P/B | P/S | ROE | EBITDA (in billions) | Gross Profit (in billions) | Revenue Growth |
|---|---|---|---|---|---|---|---|
| Merck & Co Inc | 139.38 | 7.87 | 5.20 | 12.22% | $6.96 | $12.23 | 8.89% |
| Eli Lilly and Co | 138.67 | 66.17 | 23.67 | 19.02% | $3.12 | $7.09 | 25.98% |
| Novo Nordisk A/S | 48.50 | 43.48 | 17.73 | 24.73% | $36.91 | $55.43 | 22.45% |
| Johnson & Johnson | 22.44 | 5.19 | 4.44 | 4.69% | $5.68 | $14.87 | 2.34% |
| AstraZeneca PLC | 38.81 | 6.51 | 5.16 | 5.69% | $4.47 | $10.46 | 16.55% |
| Novartis AG | 25.12 | 5.68 | 4.81 | 6.23% | $4.66 | $9.02 | 9.71% |
| Zoetis Inc | 35.24 | 16.50 | 9.65 | 11.91% | $0.93 | $1.55 | 9.5% |
| GSK PLC | 13.79 | 4.42 | 2.01 | 7.69% | $2.07 | $5.39 | 5.93% |
| Takeda Pharmaceutical Co Ltd | 46.20 | 0.92 | 1.56 | -0.04% | $86.09 | $668.37 | 9.91% |
| Dr Reddy's Laboratories Ltd | 19.62 | 3.89 | 3.91 | 4.77% | $20.32 | $41.48 | 12.49% |
| Jazz Pharmaceuticals PLC | 21.96 | 1.81 | 1.91 | -0.39% | $0.23 | $0.81 | 1.03% |
| Prestige Consumer Healthcare Inc | 17.22 | 2.15 | 3.20 | 3.04% | $0.09 | $0.15 | -3.11% |
| Corcept Therapeutics Inc | 31.75 | 6.34 | 7.03 | 5.22% | $0.03 | $0.14 | 38.95% |
| Average | 38.28 | 13.59 | 7.09 | 7.71% | $13.72 | $67.9 | 12.64% |
After thoroughly examining Merck & Co, the following trends can be inferred:
At 139.38, the stock's Price to Earnings ratio significantly exceeds the industry average by 3.64x, suggesting a premium valuation relative to industry peers.
The current Price to Book ratio of 7.87, which is 0.58x the industry average, is substantially lower than the industry average, indicating potential undervaluation.
The Price to Sales ratio is 5.2, which is 0.73x the industry average. This suggests a possible undervaluation based on sales performance.
The company has a higher Return on Equity (ROE) of 12.22%, which is 4.51% above the industry average. This suggests efficient use of equity to generate profits and demonstrates profitability and growth potential.
The company has lower Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $6.96 Billion, which is 0.51x below the industry average. This potentially indicates lower profitability or financial challenges.
The company has lower gross profit of $12.23 Billion, which indicates 0.18x below the industry average. This potentially indicates lower revenue after accounting for production costs.
The company is witnessing a substantial decline in revenue growth, with a rate of 8.89% compared to the industry average of 12.64%, which indicates a challenging sales environment.
The debt-to-equity (D/E) ratio assesses the extent to which a company relies on borrowed funds compared to its equity.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
By considering the Debt-to-Equity ratio, Merck & Co can be compared to its top 4 peers, leading to the following observations:
In terms of the debt-to-equity ratio, Merck & Co has a lower level of debt compared to its top 4 peers, indicating a stronger financial position.
This implies that the company relies less on debt financing and has a more favorable balance between debt and equity with a lower debt-to-equity ratio of 0.85.
For Merck & Co in the Pharmaceuticals industry, the high PE ratio suggests the stock is relatively expensive compared to peers. The low PB and PS ratios indicate potential undervaluation based on assets and sales. A high ROE implies strong profitability, while low EBITDA, gross profit, and revenue growth may raise concerns about operational performance within the industry sector.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: MRK
